Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 389,900 shares, a growth of 1,230.7% from the February 13th total of 29,300 shares. Based on an average trading volume of 336,300 shares, the short-interest ratio is currently 1.2 days. Approximately 2.4% of the shares of the stock are sold short.

Chemomab Therapeutics Trading Up 4.0 %

Shares of NASDAQ CMMB traded up $0.06 during mid-day trading on Wednesday, reaching $1.42. The company had a trading volume of 23,731 shares, compared to its average volume of 424,338. Chemomab Therapeutics has a 1-year low of $0.58 and a 1-year high of $2.55. The stock has a market cap of $20.32 million, a PE ratio of -1.42 and a beta of 0.54. The company has a 50-day moving average price of $1.91 and a two-hundred day moving average price of $1.75.

Wall Street Analysts Forecast Growth

CMMB has been the subject of a number of research analyst reports. Oppenheimer restated an “outperform” rating and issued a $11.00 target price (down from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th. Maxim Group boosted their price objective on Chemomab Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th.

Institutional Trading of Chemomab Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd boosted its holdings in shares of Chemomab Therapeutics by 63.8% in the fourth quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after buying an additional 9,706 shares during the period. Virtu Financial LLC acquired a new position in Chemomab Therapeutics in the 4th quarter worth approximately $26,000. Finally, Sphera Funds Management LTD. purchased a new position in Chemomab Therapeutics during the 3rd quarter worth approximately $1,907,000. Institutional investors and hedge funds own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).